For Prostate Cancer with Bone Metastases, Denosumab Prevents Skeletal Complications
the Cancer Therapy Advisor take:
Denosumab reduces risk of skeletal complications compared to zoledronic acid in patients with castration-resistant prostate cancer (CRPC) and bone metastases, according to a study published in Annals of Oncology.
Researchers led by Matthew Smith, MD, PhD, of the Massachusetts General Hospital, observed results from a phase 3 trial in order to reassess the efficacy of denosumab using symptomatic skeletal events (SSE) as the endpoint. Patients who had CRPC, were not previously exposed to bisphophonates and had radiographic evidence of bone metastasis were randomized to either denosumab 120 mg plus intravenous (IV) placebo every four weeks, or IV zoledronic acid 4 mg plus placebo every four weeks.
They found that patients with CRPC that were treated with denosumab were at a significantly reduced risk of developing first SSE, and first and subsequent SSEs, compared to those who were on zoledronic acid.
In patients who had no-to-mild pain at baseline, both SSEs and skeletal-related events (SREs) were associated with moderate-to-severe pain development. When defined as SSE versus SRE, fewer patients had skeletal complications – fractures in particular.
Denosumab reduces risk of skeletal complications compared to zoledronic acid in patients with castration-resistant prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer